Remdesivir (GS-5734) is a nucleoside analog, a broad-spectrum antiviral compound that exerts its activity by inhibiting the RNA-dependent RNA polymerase of viruses. Remdesivir is active against Ebola, SARS, and MERS viruses, and is potentially therapeutic against COVID-19.

Vero cells C1008:0.62 μM (EC50), HEp-2 cells:0.11 μM, Caco-2 cells:0.76 μM, SARS-CoV:74 nM (EC50), HeLa cells:0.1 μM (EC50), SARS-CoV-2:0.77 μM (EC50), MERS-CoV:74 nM (EC50), MHV:0.03 µM (EC50)

METHODS: Mouse hepatitis virus (MHV)-infected DBT cells were incubated with Remdesivir (0.01-1 µM) for 24 h, and the supernatant was analyzed for viral titer by plaque assay.
RESULTS: Remdesivir effectively inhibited MHV with an EC50 of 0.03 µM. [1]
METHODS: 2019-nCoV-infected Vero E6 cells were treated with Remdesivir (0-400 µM) for 48 h. Viral yield in cell supernatants was detected using qRT-PCR.
RESULTS: Remdesivir effectively blocked viral infection at low micromolar concentrations and showed high SI (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87). [2]

METHODS: To assay antiviral activity in vivo, Remdesivir (25 mg/kg, 12% sulfobutylether-β-cyclodextrin sodium salt in water (with HCl/NaOH) at pH 5.0) was injected subcutaneously into MERS-CoV-infected Ces1c-/- hDPP4 mice twice daily.
RESULTS: Prophylactic Remdesivir reduced MERS-CoV replication and disease. [3]
METHODS: To assay antiviral activity in vivo, Remdesivir (25 mg/kg once daily, administered three times) and Loratadine (10 mg/kg once daily, administered four times) were administered intraperitoneally to 501Y.V2 SARS-CoV-2 infected BALB/c mice.
RESULTS: The combination of Remdesivir and the antihistamine Loratadine reduced SARS-CoV-2 replication and inflammation and protected against lung injury. [4]